It has been a tale of two cities when it comes to Eli Lilly's operations in Puerto Rico. Its plant in Carolina has been slotted for $240 million in investments in the last year, benefiting from its buildup in insulin products, and its plant in Guayama is getting axed, a victim of patent losses.
Hospira, the country's largest producer of sterile drugs, is recalling two dozen lots of saline solution, along with 30 lots of other products, because the bags on one of its delivery systems can leak and products might get contaminated.
Novartis is reportedly caught between EU sanctions on Russia and the dictates of Russian President Vladimir Putin, who has told Western drugmakers that he expects them to build plants and transfer technology as the price of admission to the growing market.
Ceva Santé Animale, a global veterinary health group, recently inaugurated its €18 million ($23 million) renovation and extension of its sterile products plant, which will increase injectable drug production capacity.
Roche's Genentech unit is getting some high-profile blowback from a change to its distribution model on three top cancer meds. Hospital and pharmacy executives claim the new regime--which restricts Avastin, Rituxan and Herceptin to a half-dozen specialty distributors--will cost them big money.
Tuesday, Valeant Pharmaceuticals said the FDA had served up a warning letter about its Sculptra Aesthetic manufacturing, citing problems it observed during a June 2014 inspection. The missteps from manufacturing standards might just fuel the fire from hostile buyout target Allergan.
Gilead Sciences is plotting a new, 400,000-square-foot manufacturing site near its current plant in San Dimas, CA, local media reports.
The animal health industry is seeing robust activity in Brazil these days. Merial, Sanofi's animal health company, announced it is pouring $25 million into its Paulínia, Brazil, plant to increase the production of NexGard, the chewable flea and tick treatment for dogs introduced this year.
Roche is again tracking down counterfeits of some of its cancer meds in Europe after an importer in Germany discovered the fakes. In this case, it is counterfeit MabThera, sold as Rituxan in the U.S.
Is it possible to be just too clever when it comes to marketing? That is something that Actavis CEO Brent Saunders will find out now that his decision to stop making the original version of the Alzheimer's treatment Namenda has turned into a production pileup for the company.